PD-1增强型HIV-1治疗性DNA疫苗ICVAX的I期安全性及免疫原性
在深圳第三人民医院开展的NMPA批准、随机双盲安慰剂对照剂量递增I期试验(NCT06253533)纳入45例接受ART的18-50岁HIV-1感染者,评估PD-1增强型HIV-1治疗性DNA疫苗ICVAX。全部45例完成试验,治疗相关不良事件均为轻度和一过性,以局部反应为主;ICVAX可诱导较强的抗原特异性T细胞应答。
要点
- ICVAX联合电穿孔肌注在ART抑制的HIV-1感染者中耐受良好,不良事件以轻度局部反应为主。
- 低、中、高剂量组分别有75%、75%、58.3%的受者ELISpot T细胞应答峰值较基线升高≥2倍,安慰剂组为33.3%。
- ICVAX受者出现表达CD107a和/或效应细胞因子的低频Gag特异性T细胞。
核心结论
- ICVAX耐受良好,并在ART抑制的HIV-1感染者中诱导稳健的抗原特异性T细胞应答。
- 其疗效将在未来研究中评估。
研究设计与样本
- NMPA批准、随机、双盲、安慰剂对照、剂量递增I期临床试验(NCT06253533),在深圳第三人民医院开展。
- 纳入18-50岁接受ART的HIV-1成人,序贯分配至1、2、4 mg剂量组,每组15例,按12:3随机接受ICVAX或安慰剂。
- 第0、4、8、12、36周经肌内注射联合电穿孔给药;主要终点为安全性,次要终点为免疫学,探索性终点为病毒学。
主要发现
- 全部45例完成试验,每个ICVAX队列12例,安慰剂合并组9例。
- 治疗相关不良事件发生率:安慰剂100%、ICVAX受者83.3%,均为轻度和一过性,以局部反应为主。
- ELISpot T细胞应答峰值较基线升高≥2倍者:低剂量组75%、中剂量组75%、高剂量组58.3%,安慰剂组33.3%。
- ICVAX受者可见表达CD107a和/或效应细胞因子的低频Gag特异性T细胞。
临床怎么用
- 该I期结果支持ICVAX作为ART抑制HIV-1感染者的治疗性疫苗候选进入后续疗效研究。
- 临床应用中需关注以局部反应为主的轻度一过性不良事件。
局限性
- 为I期小样本剂量递增研究,主要评价安全性与免疫原性,疗效尚未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic vaccines represent a potential strategy for HIV-1 control without antiretroviral therapy (ART). We report a first-in-human study on ICVAX™, a PD-1-enhanced HIV-1 therapeutic DNA vaccine. METHODS: This NMPA-approved, randomized, double-blind, placebo-controlled, dose-escalation phase I trial (NCT06253533) was conducted at Shenzhen Third People's Hospital, China. Adults with HIV-1 aged 18-50 years on ART were sequentially allocated to 1, 2, or 4 mg dose groups of 15, each randomized 12:3 to ICVAX or placebo. Participants received intramuscular injections with electroporation at Weeks 0, 4, 8, 12, and 36. Primary safety, secondary immunological, and exploratory virological outcomes were recorded. RESULTS: All 45 participants completed the trial, with 12 per ICVAX cohort and 9 in pooled Placebo. Treatment-related adverse events occurred in 100% of placebo and 83.3% of ICVAX recipients, all mild and transient, predominantly local reactions. A ≥2-fold increase of peak ELISpot T-cell responses over baseline was achieved by 75%, 75%, and 58.3% of low-dose, mid-dose, and high-dose recipients, versus 33.3% for Placebo. ICVAX recipients also showed low-frequency Gag-specific T cells expressing CD107a and/or effector cytokines. CONCLUSIONS: ICVAX was well-tolerated and elicited robust antigen-specific T-cell responses in ART-suppressed people with HIV-1. Its efficacy will be assessed in future studies.
引用
- Peng Q, Wong YC, Cheng WY, et al. Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy. J Infect Dis. 2026. PMID: 42446368. doi:10.1093/infdis/jiag320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。